MISSION
R-PHARM Close Joint Stock Company sees its mission in provision of institutions and organizations operating in the public health system of the Russian Federation with specific medicines for the purpose of realization of high-quality treatment schemes.

OVERVIEW
R-Pharm is a Russian drug producer that has focused on the hospital sector from the time the company was founded. Our Yaroslav production facilities aim to provide import substitution in order to reduce the cost of drug purchases.
The company currently employs 325 highly-qualified specialists and has 12 branches and representative offices across Russia. These numbers are poised to grow rapidly after the planned launch of our in-house production capacity.
R-Pharm is a leading Russian distributor of pharmaceuticals and offers the full spectrum of services in this sector. Strict attention is paid to handling temperature-sensitive drugs in all stages of drug transport and storage (cold chain management).
Starting in 2007, the company has been an active player in Additional Pharmaceutical Support programs that provide necessary drugs to various segments of the population.

WHAT MAKES US DIFFERENT
IN-HOUSE PRODUCTION
R-Pharm’s investment project to launch drug production in Yaroslavl is an excellent example of how well our strategy fits current socioeconomic realities of the Russian Federation.
Even during the first planning stages of the project, R-Pharm designed the plant to fully meet GMP requirements. This was unprecedented in Russia, particularly in the sphere of producing sterile injectable drugs. The project will produce drugs to treat key socially significant diseases, including cancers, hematologic illnesses, arthritis, diabetes, viral hepatitis, HIV, and severe bacterial and fungal infections.

SALES AND MARKETING
Our Sales and Marketing departments complement each other within R-Pharm’s structure.
These departments design and develop sales plans for high-priority products, organize scientific conferences and maintain relations with various federal and regional scientific establishments. All of the employees in R-Pharm’s Marketing Department have a background working for Western drug companies. This facilitates maintaining a dialog with production companies and increases the productivity of our work with these companies.

SOCIAL POSITIONING
One of the R-Pharm’s priorities is to distribute orphan drugs. The company is participating, together with various patients’ associations, in the creation of a register of patients that suffer from various rare diseases (including hemophilia, myeloma, muscular sclerosis and others). We are also active participants in specialized medical forums and conferences on this topic.
R-Pharm is actively developing our charitable activities. One notable example was our sponsorship of a benefit concert organized by Chulpan Khamatova’s Give Life foundation in May 2009.

THE DRUGS WE SELL
R-Pharm’s clients include leading federal medical research centers, military hospitals and clinics, and leading regional healthcare facilities, particularly cancer diagnostic facilities and clinical hospitals. We also service other players in the pharmaceutical market, including large state and municipal pharmaceutical warehouses and pharmacies and commercial distributors in the Russian regions.
R-Pharm specializes in the delivery of high-tech drugs required by the hospital sector. We provide drugs from various clinical drug groups, including oncologic, hematologic, immunologic, antibacterial, antiviral (including HIV therapy), organ transplant medication, and drugs to treat muscular sclerosis, hemophilia and diabetes. We also offer neuromuscular relaxants, radiocontrast agents and anesthesia.

WHERE WE’RE HEADING
R-Pharm is committed to maintaining intensive growth that outstrips the market (by more than 50% annually), expanding our product assortment to fit the needs of Russian citizens for high-tech innovative drugs. We are actively expanding our product assortment and cover all segments of the pharmaceutical market, including vaccines, consumables and parenteral nutrition.
In-house production will create an unprecedented competitive advantage as we strive to hit our targets and fulfill customer demands for drugs needed for modern medical and prophylactic treatments.